HOLX - FDA OKs emergency use of Hologic high-throughput COVID-19 molecular test

Hologic (HOLX) announces emergency use authorization in the U.S. for its Panther Fusion SARS-CoV-2 molecular assay for use in testing asymptomatic people for COVID-19 infection (in other words, the high-throughput test can be used to screen people who may have been exposed to an infected person).The automated Panther Fusion system can generate initial results in ~three hours and more than 1,000 coronavirus tests in 24 hours.Shares up 3% premarket on light volume.

For further details see:

FDA OKs emergency use of Hologic high-throughput COVID-19 molecular test